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Abstract
An important pathological feature of Alzheimer’s disease (AD) is the presence of extracellular senile plaques in the
brain. Senile plaques are composed of aggregations of small peptides called b-amyloid (Ab). Multiple lines of
evidence demonstrate that overproduction/aggregation of Ab in the brain is a primary cause of AD and inhibition
of Ab generation has become a hot topic in AD research. Ab is generated from b-amyloid precursor protein (APP)
through sequential cleavages first by b-secretase and then by g-secretase complex. Alternatively, APP can be
cleaved by a-secretase within the Ab domain to release soluble APPa and preclude Ab generation. Cleavage of
APP by caspases may also contribute to AD pathologies. Therefore, understanding the metabolism/processing of
APP is crucial for AD therapeutics. Here we review current knowledge of APP processing regulation as well as the
patho/physiological functions of APP and its metabolites.
Background
Alzheimer’s disease (AD) is the most prevalent neurode-
generative disorder, afflicting 10% of the population over
the age of 65 and 50% of the population over the age of
85. A small subset (<10%) of AD cases result from an
inherited autosomal dominant gene mutation and have
an early-onset (the fourth to sixth decade). The majority
of these familial AD (FAD) mutations are in the genes
encoding b-amyloid precursor protein (APP) and prese-
nilins (PS1 and PS2) [1-3]. Significant efforts have gone
into understanding the mechanisms underlying the
genes tied to FAD as the clinicopathological features are
indistinguishable from regular onset AD.
AD is characterized in patients by an inexorably pro-
gressing dementia. In vulnerable brain regions, such as
the hippocampus and cortex, there is an accumulation
of extracellular neuritic plaques and intracellular neuro-
fibrillary tangles. The neurofibrillary tangles (NFTs) con-
sist largely of hyperphosphorylated twisted filaments of
the microtubule-associated protein tau [4,5]. Extracellu-
lar neuritic plaques are deposits of differently sized
small peptides called b-amyloid (Ab) that are derived via
sequential proteolytic cleavages of the b-amyloid precur-
sor protein (APP) [6].
APP and Its Function
The APP gene is located on chromosome 21 in humans
with three major isoforms arising from alternative
splicing [3]. These are APP695, APP751 and APP770
(containing 695, 751, and 770 amino acids, respectively).
APP751 and APP770 are expressed in most tissues and
contain a 56 amino acid Kunitz Protease Inhibitor (KPI)
domain within their extracellular regions. APP695 is
predominantly expressed in neurons and lacks the KPI
domain [7,8]. There are reports showing that the protein
and mRNA levels of KPI-containing APP isoforms are
elevated in AD brain and associated with increased Ab
deposition [9]; and prolonged activation of extrasynaptic
NMDA receptor in neurons can shift APP expression
from APP695 to KPI-containing APP isoforms, accom-
panied with increased production of Ab [10]. These
findings may suggest that a dysregulated splicing of APP
RNA contributes to disease pathogenesis.
APP belongs to a protein family that includes APP-
like protein 1 (APLP1) and 2 (APLP2) in mammals
[11-13], all are type-I transmembrane proteins and are
processed in a similar fashion. The Ab domain is unique
to the APP protein, though the family shares several
other conserved domains such as the E1 and E2
domains in the extracellular sequence. Studies with APP
knockout mice suggest some functional redundancy
between these APP homologs that appears to be exerted
by motifs other than Ab. APP knockout mice are viable
and fertile, showing a relatively subtle abnormal pheno-
type [14,15]. APLP1 and APLP2 knockout mice are also
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APLP2 double null mice and APP/APLP1/APLP2 triple
null mice show early postnatal lethality [16-18]. Interest-
ingly, the APP/APLP1 double null mice are viable [17],
suggesting that APLP2 is crucial when either APP or
APLP1 is absent.
Although APP has been the subject of much study
since its identification, its physiological function remains
largely undetermined. A role for APP has been sug-
gested in neurite outgrowth and synaptogenesis, neuro-
nal protein trafficking along the axon, transmembrane
signal transduction, cell adhesion, calcium metabolism,
etc, all requiring additional in vivo evidence (reviewed
in [19]). APP is proteolyzed into various fragments
(see Figure 1) during its intracellular trafficking and
these APP metabolites mediate various and sometimes
adverse functions. Therefore, the net effect of full-length
APP on cellular activity may be a combination of its
metabolites’ functions, temporospatially depending on
the proportion of levels of each APP metabolite. Here we
list several possible functions of full-length APP per se.
T h es i m i l a r i t yi nt o p o l o g ya n dp r o t e o l y t i cp r o c e s s i n g
between APP and Notch suggest that APP may function
as a membrane receptor like Notch. Indeed, several APP
ligands have been identified, such as Ab [20], F-spondin
[21] and nectrin-1 [22]. However, while binding of APP
by these ligands can affect APP processing, the exact
downstream signaling events triggered by such binding
remains to be clarified and a bona fide membrane recep-
tor function for APP remains speculative.
There is evidence linking APP to cell adhesion. APP
was found to colocalize with b1i n t e r g r i n si nn e u r a l
cells [23]. An X-ray analysis showed that the E2 domain
of APP can form antiparallel dimers [24]. Indeed,
further study in cell cultures demonstrated that APP
can form homodimers and heterodimers in a trans-
dimerization manner with other APP family members
and that such dimerization promotes intercellular adhe-
sion [25].
APP undergoes rapid anterograde transport in neu-
rons. During its transport, APP was found to interact
with kinesin-I and functions as a kinesin-I membrane
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Figure 1 Schematic diagram of APP processing (not drawn in proportion). It is not clear whether caspases cleave membrane-associated
APP forms or released AICD.
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Page 2 of 13receptor to mediate axonal transport of b-secretase
(BACE1) and PS1 [26,27]. However, another study failed
to verify the interaction between APP and kinesin-I and
the co-transport of BACE1 and PS1 with APP [28]. We
r e c e n t l yf o u n dt h a tA P Pa n di t sd e r i v e dm e m b r a n e -
associated form, CTFs, can regulate cell surface delivery
of PS1/g-secretase but not BACE1 [29]. In addition, APP
was found to be a major component of herpes simplex
viral particles and likely mediates fast anterograde trans-
port of these particles [30,31]. Another study showed
that increased doses of APP markedly decreased retro-
grade transport of nerve growth factor and resulted in
degeneration of forebrain cholinergic neurons in a
mouse model of Down’s Syndrome [32]. APP was also
found to interact with high-affinity choline transporter
(CHT) through the C-terminal domain and APP defi-
ciency affected CHT endocytosis [33]. Overall, most stu-
dies suggest that APP plays some role in regulating
protein trafficking.
APP Processing
Full-length APP is a type I transmembrane protein. APP
is synthesized in the endoplasmic reticulum (ER) and
then transported through the Golgi apparatus to the
trans-Golgi-network (TGN) where the highest concen-
tration of APP is found in neurons at steady state
[34-36]. Ab is generated in the ER and Golgi/TGN [36].
From the TGN, APP can be transported in TGN-
derived secretory vesicles to the cell surface where it is
either cleaved by a-secretase to produce a soluble mole-
cule, sAPPa [37], or re-internalized via an endosomal/
lysosomal degradation pathway [38,39]. It has been pro-
p o s e dt h a tA b can also be generated in the endosomal/
lysosomal system [40,41]. While Ab is neurotoxic, stu-
d i e ss u g g e s tt h a ts A P P a is neuroprotective, making the
subcellular distribution of APP an important factor in
neurodegeneration [42-44]. Delineation of the mechan-
isms involved in APP trafficking are thus relevant and
crucial to understanding the pathogenesis of AD.
a-secretase and a-processing
Cleavage of APP by a-secretase precludes Ab generation
as the cleavage site is within the Ab domain (at the Lys16-
Leu17 bond), and releases a large soluble ectodomain of
APP called sAPPa. The generation of sAPPa is a constitu-
tive event but can also be regulated by various reagents.
Early studies suggested that a-secretase is a membrane-
bound endoprotease which cleaves APP primarily at the
plasma membrane [37]. Using proteinase inhibitor profil-
ing, it was determined that a-secretase is a zinc metallo-
proteinase [45]. Several members of the ADAM (a
disintegrin and metalloproteinase) family possess a-secre-
tase-like activity and three of them have been suggested as
the a-secretase: ADAM9, ADAM10, and ADAM17. Like
APP, they are also type-I transmembrane proteins.
ADAM17 (also called tumor necrosis factor-a con-
verting enzyme, TACE) can be proteolytically cleaved to
release its extracellular domain as soluble TGF-a [46].
Manipulation of ADAM17 can alter a-cleavage of APP
and Ab generation, with regulated a-cleavage abolished
in ADAM17-deficient cells, suggesting that ADAM17 is
likely the a-secretase responsible for regulated APP
cleavage [47]. Additionally, an ADAM17 inhibitor pre-
vented regulated a-secretase activity in human neurons
[48], whereas RNAi downregulation of ADAM10 had no
effect on a-cleavage of APP [49]. Various other studies
confirm that ADAM17 likely affects regulated, but not
constitutive, a-cleavage in various cell lines [50].
Co-expression of ADAM9 with APP promoted sAPPa
production upon phorbol ester treatment, suggesting
that ADAM9 possesses a-secretase activity [51]. How-
ever, RNAi of ADAM9 had no effect on sAPPa genera-
tion [49], implying that ADAM9 is involved only in
regulated a-cleavage.
Overexpression of ADAM10 increases a-cleavage,
whereas a dominant-negative form of ADAM10 and
RNAi of ADAM10 inhibit endogenous a-cleavage activ-
ity in several cell lines, including murine primary neu-
rons [49,52,53]. Significantly, sAPPa generation was
nearly abolished in the neurons of mice with neural
ADAM10 conditionally knocked-out [54]. A dramati-
cally reduced ADAM10 protein level in the platelets of
sporadic AD patients was also found to correlate with
the significantly decreased sAPPa levels found in their
platlets and cerebrospinal fluid [55] and the reduced a-
secretase activity in the temporal cortex homogenates of
AD patients [56]. These studies strongly suggest that
ADAM10 is the constitutive a-secretase that is active at
the cell surface, though there may be some functional
redundancy in a-cleavage among the ADAM family.
In contrast to Ab,s A P P a has an important role in
neuronal plasticity/survival and is protective against
excitotoxicity [42,43]. sAPPa also regulates neural stem
cell proliferation and is important for early CNS devel-
opment [57,58]. We and others have also found that
sAPPa can inhibit stress-induced CDK5 activation and
participate in various neuroprotective reagent-mediated
excitoprotection [44,59-61]. Interestingly, expression of
sAPPa a l o n ei sa b l et or e s c u et h ea b n o r m a l i t i e so fA P P
deficient mice [62], implying that most of APP’sp h y s i o -
logical function is mediated by sAPPa.
b-secretase and b-processing
The first step in Ab generation is cleavage of APP by the
b-secretase. In 1999-2000, several groups concomitantly
identified BACE1 (also called Asp2 or memapsin 2) as the
major b-secretase [63-66]. BACE1, the most common
name for the protease, is a membrane-bound aspartyl
protease with a characteristic type I transmembrane
domain near the C-terminus [63,64]. Overexpression or
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APP at the known b-site locations, Asp1 and Glu11,
respectively. In vitro studies with synthetic APP peptides
confirm cleavage by BACE1. These results provide convin-
cing evidence that BACE1 is the b-secretase involved in
APP metabolism [63-67]; and BACE1 activity is thought
to be the rate-limiting factor in Ab generation from APP.
A larger precursor, pro-BACE1, is modified by glyco-
sylation, phosphorylation and cleaved by a furin-like
endoprotease to produce mature BACE1 [68,69]. BACE1
requires an acidic environment for optimal activity and,
as expected, overexpressed BACE1 in various pre-mito-
tic cell lines is mainly found in the early Golgi, late
Golgi/early endosomes, and endosomes that provide an
acidic environment. In addition, BACE1 can be found at
the cell surface [64,70-72]. The mechanisms regulating
BACE1 trafficking and activity have not been fully eluci-
dated. Some studies found that BACE1 can interact with
reticulon/Nogo proteins, whose increased expression
can block BACE1 in the ER with a neutral pH environ-
ment and thus inhibit BACE1 activity in Ab generation
[73-75]. On the other hand, Golgi-localized g-ear-con-
taining ARF-binding (GGA) proteins have been found to
interact with BACE1 and regulate its trafficking between
the late Golgi and early endosomes; and depletion of
GGA proteins increases the accumulation of BACE1 in
acidic early endosomes for enhanced BACE1 stability
and cleavage of APP [76-78].
The viability of BACE1 as a therapeutic target has
been investigated by a number of studies. An early study
suggested that BACE1 knockout mice do not produce
detectable levels of Ab and have no severe phenotypic
abnormalities [79]. BACE1 deficiency in AD model mice
have been shown to rescue cholinergic dysfunction, neu-
ronal loss and memory deficits, correlating with a dra-
matic reduction in Ab40/42 levels [79-81]. Several
studies have found that BACE1 protein and activity
levels are elevated in the regions of the brain affected by
AD [82,83]. Together these results suggest BACE1 as a
good therapeutic target for AD. However, more recent
studies have found several phenotypic abnormalities in
BACE1 KO mice. Dominguez et al. [84] observed a vari-
able but significant number of BACE1 null mice died in
the first weeks after birth. The BACE1 null mice that
survive were smaller than their littermates, presented
with hyperactive behavior, and had subtle electrophysio-
logical alterations in the steady-state inactivation of
their voltage-gated sodium channels. They also were
affected by hypomyelination of peripheral nerves and
had altered neurological behaviors such as reduced grip
strength and elevated pain sensitivity, likely due to the
deficiency of neuregulin processing in the absence of
BACE1, as neuregulin 1 is another substrate of BACE1
[85,86]. Furthermore, additional BACE1 substrates have
been identified, including the voltage-gated sodium
channel (Nav1) b2 subunit, Golgi-localized membrane-
bound a2,6-sialyltransferase, P-selectin glycoprotein
l i g a n d- 1 ,e t c .( r e v i e w e di n[87]). Therefore, BACE1 is
likely not as safe a drug target as first assumed.
BACE2 is a homolog of BACE1 that maps to 21q22.3
[88], the region critical for Down’s syndrome (DS). As
DS also results in Ab accumulation, the genes location
suggests a link between BACE2 and APP processing.
Indeed, BACE2 cleaves b-secretase substrates such as
wild-type and Swedish mutant APP, similar to BACE1,
in enzymatic In vitro assays [89]. However, BACE2
expression in neurons is substantially lower than BACE1
[90] and cellular BACE2 cleaves APP near the a-secre-
tase site much more efficiently than at the b-secretase
site [91]. These results suggest that BACE1 is the pri-
mary b-secretase but do not exclude a potential contri-
bution of BACE2 towards AD pathogenesis. While
BACE2 knockout mice are healthy overall, a deficiency
of both BACE1 and BACE2 enhanced the BACE1 KO
lethality phenotype, suggesting a slight functional redun-
dancy [84].
In addition to BACE1 and BACE2, cathepsin B has
been proposed as an additional b-secretase. Inhibition of
cathepsin B has been found to reduce Ab production
both in vivo and in vitro [92,93]. However, whether
cathepsin B really exerts physiological b-secretase activ-
ity requires further validation.
Upon b-cleavage, the ectodomain of APP is also
released as soluble APPb (sAPPb). Although sAPPb only
differs from sAPPa by lacking the Ab1-16 region at its
carboxyl-terminus, sAPPb was reported to function as a
death receptor 6 ligand and mediate axonal pruning and
neuronal cell death [94]. A recent report found that
sAPPb can rescue gene expression of transthyretin and
Klotho, which is decreased in APP/APLP2 deficient
mice, but cannot rescue the lethality and neuromuscular
synapse defects of these mice, suggesting a gene expres-
sion regulation function for sAPPb that is independent
of developmental APP functions [95].
After a-a n db-cleavage, the carboxyl terminal frag-
ments (CTFs) of APP, known as aCTF and bCTF,
respectively, remain membrane-associated and will be
further cleaved by g-secretase. Since these APP CTFs
are intermediate products, their functions have been less
characterized. However, overexpression of APP bCTF
was found to be cytotoxic and cause neuronal degenera-
tion, perhaps by perturbing APP signal transduction
[96,97]. It is also possible that APP bCTF’s cytotoxic
effect is actually mediated by the end products of
g- and/or caspase-cleavage including APP intracellular
domain (AICD), C31 and Jcasp which are cytotoxic (see
below). We recently found that APP bCTF can regulate
cell surface delivery of g-sceretase, perhaps through the
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that APP aCTF possesses a similar effect since it is also
the substrate of g-secretase.
g-secretase and g-processing
APP aCTF and bCTF are further cleaved by g-secretase
to generate p83 and Ab, respectively. The p83 fragment
is rapidly degraded and widely believed to possess no
important function, if any. g-secretase-mediated cleavage
is unique in that the cleavage takes place within the
transmembrane domain, though the exact site can vary.
g-cleavage can yield both Ab40, the majority species,
and Ab42, the more amyloidogenic species, as well as
release the intracellular domain of APP (AICD). Recent
data has shown that PS/g-secretase also mediates ζ-site
cleavage (Ab46) [98,99] and ε- s i t ec l e a v a g e( A b49)
[100,101], suggesting a sequential cleavage model where
cleavage at the ε-site is followed by the ζ-site and g-site.
Multiple lines of biochemical evidence have shown g-
secretase activity to reside in a high molecular weight
complex consisting of at least four components: preseni-
lin (PS, PS1 or PS2), Nicastrin, anterior pharynx-defec-
tive-1 (APH-1), and presenilin enhancer-2 (PEN-2)
[102,103]. In mammals there are two presenilin homo-
logs, PS1 and PS2 [1,2]. Mutations in these two genes,
particularly PS1, are causative in the majority of familial
AD (FAD) cases. PSs are multi-transmembrane proteins
with an unclear number of transmembrane domains
[104]. Nascent PSs undergo endroproteolytic cleavage
with the resulting amino-terminal fragment (NTF) and
carboxyl-terminal fragment (CTF) forming a functional
PS heterodimer [105]. PSs possess two highly conserved
aspartate residues indispensable for g-secretase activity.
The PS1 NTF/CTF heterodimers are bound by transi-
tion-state analogue g-secretase inhibitors [102,106], sug-
gesting that PSs are the crucial catalytic components of
g-secretase. This notion has recently been confirmed by
in vitro assays [107]. Nicastrin, the first identified cofac-
tor of PS, is a type I transmembrane glycoprotein that is
considered the scaffolding protein within the g-secretase
complex. One study showed that the ectodomain of
Nicastrin binds to APP and Notch and can recruit them
into the g-secretase complex, suggesting that Nicastrin
may act as the g-secretase receptor [108]. Another two
components, APH1 and PEN2, were identified through
genetic screening of Caenorhabditis elegans [109,110].
APH-1 interacts with Nicastrin to form a stable inter-
mediate in an early assembly stage of the g-secretase
complex [102]. PEN-2 regulates PS endoproteolysis
[107,108]. Each of these four g-secretase components
has been found necessary for the enzymatic activity of
the complex with deficiency in any of them dramatically
impairing g-secretase activity. Coexpression of the four
components in the yeast Saccharomyces cerevisiae has
been found to be necessary and sufficient to reconstitute
g-secretase activity, which is not endogenous to yeast
[111,112].
In addition to the four critical components, several
other factors have been proposed as additional g-secre-
tase components. However, these factors play a modula-
tory role and are not essential for g-secretase activity:
CD147 is a transmembrane glycoprotein and interacts
with all four essential g-secretase components. Downre-
gulation of CD147 increases Ab production but its over-
expression has no effect on Ab generation [113].
TMP21/p23 binds to the g-secretase complex and
regulates g-cleavage, but not ε-cleavage, through its
transmembrane domain [114,115]. However, another
study failed to confirm the binding of TMP23/p21 to
g-secretase, but rather suggested that TMP21/p23,
which belongs to the p24 cargo family involved in vesi-
cular trafficking regulation, influences APP trafficking
and thus Ab generation [116]. Recently, a novel g-secre-
tase activating protein (GSAP) was identified and GSAP
was found to selectively increase Ab production through
interaction with both g-secretase and the APP CTF
substrate [117]. Additional validation and investigation
of the role of these proteins in the g-secretase complex
is required.
Strong evidence suggests that the g-secretase complex
resides primarily in the ER, Golgi/TGN, endocytic and
intermediate compartments–most of which (except the
TGN) are not major subcellular localizations for APP
[118,119]. In addition to cleaving APP CTFs, g-secretase
cleaves a series of functionally important transmem-
brane proteins, including Notch [120], cadherin [114],
tyrosinase [121], ErbB4 [79], CD44 [70], etc.) (see review
[122]). The cleavage of various substrates appears to be
dependent on the subcellular compartment; APP is
mainly cleaved in the TGN and early endosomal
domains whereas Notch is primarily cleaved at the
plasma membrane [34,36,123]. Thus a disturbance in
the localization of the g-secretase complex may play
some role in abnormal Ab generation and AD
pathogenesis.
g-cleavage can release the intracellular domains (ICDs)
of the substrates. Notch intracellular domain (NICD) is
well-known to translocate into the nucleus and regulate
genes critical to development [124,125]. The other intra-
cellular domains may be of comparable importance. For
example, the ErbB4 ICD has been found to bind to
astrocytic gene promoters to suppress their expression
[126]. In a similar fashion, released AICD has been
shown to possess transactivation activity and can regu-
late transcription of multiple genes including APP, GSK-
3b, KAI1, neprilysin, BACE1, p53, EGFR, and LRP1
[127-132]. In addition, free AICD can induce apoptosis
and may play a role in sensitizing neurons to toxic sti-
muli [133,134]. However, as the intracellular domain of
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interaction of APP with various cytosolic factors that
regulate APP’s intracellular trafficking and/or signal
transduction function. Interestingly, it seems that AICD-
mediated APP interaction with different factors is con-
trolled by the phosphorylation state of AICD [135].
Caspase processing
In addition to secretases, caspases (predominantly cas-
pase-3) can directly cleave APP at position Asp664
(based on the APP695 sequence) within the cytoplasmic
tail during apoptosis to release a fragment containing
the last 31 amino acids of APP (called C31). Additional
g-cleavage further generates the fragment (called Jcasp)
containing the region between g- and caspase-cleavage
sites [136-138]. Although original data found that cas-
pase cleavage affects amyloidogenic processing of APP
[137], further study suggests not [139]. However, during
Ab-induced neurotoxicity, activated caspases cleave APP
to generate C31 and Jcasp, which are also neurotoxic,
therefore initiating a detrimental cascade [140]. One
possible mechanism for C31’st o x i c i t yi st h a tC 3 1c o m -
plexes with APP to recruit the interacting partners that
initiate the signals related to cellular toxicity [136].
Compared to C31, Jcasp appears to play a minor role in
cytotoxicity [136]. Importantly, caspase cleavage of APP
seems to be crucial for Ab-mediated neurotoxicity, as an
APP mutation at position Asp664 to inhibit the caspase-
cleavage in transgenic mice negated the synapse, electro-
physiology, and behavioral abnormalities, even though
Ab plaques were still abundant in the brain [141].
Ab Function
T h en e u r o t o x i ce f f e c to fA b has been well-established
and will not be specifically emphasized here. Multiple
lines of evidence demonstrate that overproduction of Ab
results in a neurodegenerative cascade leading to synap-
tic dysfunction, formation of intraneuronal fibrillary tan-
gles and eventually neuron loss in affected areas of the
brain [6,142]. There are two main toxic species, Ab40
and Ab42, with Ab42 more hydrophobic and more
prone to fibril formation while only making up about
10% of the Ab peptide produced [143]. Studies done on
familial AD (FAD) mutations consistently show
increases in the ratio of Ab42/40 [105,144], suggesting
that elevated levels of Ab42 relative to Ab40 is critical
for AD pathogenesis, probably by providing the core for
Ab assembly into oligomers, fibrils and amyloidogenic
plaques [145,146].
Although the majority of Ab is secreted out of the
cell, Ab can be generated in several subcellular compart-
ments within the cell, such as the ER, Golgi/TGN, and
endosome/lysosome. In addition, extracellular Ab can be
internalized by the cell for degradation. The intracellular
existence of Ab implies that Ab may accumulate within
neurons and contribute to disease pathogenesis. Con-
firming this, intraneuronal Ab immunoreactivity has
been found in the hippocampal and entorhinal cortical
regions which are prone to early AD pathology in
patients with mild cognitive impairment (MCI) [147]. In
Down Syndrome (DS) patients, the accumulation of
intracellular Ab precedes extracellular plaque formation
[148] and the level of intraneuronal Ab decreases as the
extracellular Ab plaques accumulate [149]. Studies with
transgenic mouse models consistently confirm these
results, revealing intracellular Ab accumulation as an
early event in the neuropathological phenotype with
decreasing intraneuronal levels of Ab as extracellular
plaques build up [150-152]. Intraneuronal Ab can also
impair amygdala-dependent emotional responses by
affecting the ERK/MAPK signaling pathway [153]. Inhi-
bition of dynamin-mediated but not clathrin-mediated
Ab internalization was also found to reduce Ab-induced
neurotoxicity [154]. One recent study suggests that
internalized Ab can aggregate within the cell and disrupt
the vesicular membrane, thus contributing to its patho-
logical effect [155].
Ab was originally regarded as an abnormal and toxic
species restricted to the brains of aged or demented
humans. The discovery of soluble Ab species in the bod-
ily fluids of various species [156] and in the conditioned
medium of cultured cells [157] has refuted this concept
and implied a physiological function for Ab.A l t h o u g h
excessive Ab causes synaptic dysfunction and synapse
loss [142], low levels of Ab increase hippocampal long-
term potentiation and enhances memory, indicating a
novel positive, modulatory role on neurotransmission
and memory [158,159]. Picomolar levels of Ab can also
rescue neuronal cell death induced by inhibition of Ab
generation (by exposure to inhibitors of b-o rg-scre-
tases) [160], possibly through regulating the potassium
ion channel expression, hence affecting neuronal excit-
ability [161]. One study using a transgenic Caenorpabdi-
tis elegans model found that intracellular Ab
aggregation in muscle cells may trap excess free copper
to reduce copper-mediated cytotoxic effects [162]. How-
ever, whether Ab can form intracellular aggregates in
human peripheral cells to exert a physiologically protec-
tive function remains to be determined.
Regulation of APP Processing at the Trafficking Level
Alterations in APP intracellular trafficking and localiza-
tion directly impact Ab production as APP is processed
by two mutually exclusive pathways. The available evi-
dence has shown that intracellular trafficking of APP is
regulated by a number of factors.
Trafficking factors
Intracellular trafficking of proteins requires the involve-
ment of a series of cytosolic factors. An increasing
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ficking factors are being implicated in the regulation of
Ab generation and APP trafficking. For example, the
APP C-terminus has been found to interact with all
three mint (X11) family members (mint1, mint2, and
mint3) involved in trafficking regulation [163-165]. APP
interaction with mint proteins has been shown to affect
APP processing by stabilizing cellular APP, altering both
sAPPa and Ab generation and secretion [166]. Rab6, a
member of the GTP-binding protein family of mem-
brane trafficking regulators, is implicated in protein
transport along biosynthetic and endocytic pathways
and has also been found to affect APP processing.
Moreover, internalization of APP from the cell surface
for endosomal/lysosomal degradation can be mediated
by clathrin. Clathrin-modulated endocytosis is tightly
controlled, requiring the participation of AP-2, dynamin
I, and many other factors [167-169]. When the endocy-
tic pathway is inhibited by overexpression of a domi-
nant-negative form of dynamin I, APP processing is also
affected [170,171]. It is conceivable that other important
vesicular transport factors may also affect APP proces-
sing through regulation of general protein trafficking.
In addition to general trafficking modulators, several
other proteins have been found to regulate APP traffick-
ing in a more specific manner, possibly through their
direct binding to APP. PS1 is the catalytic component of
the g-secretase complex but has also been demonstrated
to regulate the intracellular trafficking of several mem-
brane proteins, including the other g-secretase compo-
nents (nicastrin, APH-1 and PEN-2), TrkB, and ICAM-
5/telecephalin [122]. We and others have shown that
PS1 can also regulate the intracellular trafficking of
APP. Expression of a loss of function PS1 variant, or the
absence of PS1, results in increased budding/generation
of vesicles from both the ER and TGN containing APP
along with a concomitant increase in complex glycosyla-
tion and APP localization at the cell surface. In contrast,
the FAD-linked PS1 mutant variants significantly reduce
b u d d i n gf r o mt h eE Ra n dT G Na n dr e s u l ti nd e c r e a s e d
delivery of APP to the cell surface [172]. These results
suggest the possibility that FAD-linked PS1 variants
increase Ab production by decreasing intracellular trans-
port of APP, prolonging the availability of APP for clea-
vage by b-a n dg-secretases within the TGN. PS1 may
regulate protein trafficking through its interaction with
several cytosolic factors involved in the regulation of
vesicular transport such as Rab11, Rab6 and Rab GDI
[173-175]. We have also found that PS1 interacts with
phospholipase D1 (PLD1), a phospholipid-modifying
enzyme regulating membrane trafficking events. This
PS1-PLD1 interaction recruits PLD1 to the Golgi/TGN
and thus potentially alters APP trafficking as PLD1 over-
expression promotes budding of vesicles from the TGN
containing APP and increases cell surface levels of APP
[176,177].
SorLA/LR11 is a type I membrane protein expressed
in neurons and reduced in the brains of AD patients
[178,179]. Although the function of SorLA/LR11 is not
known, its homology with sorting receptors that are
involved with transport between the plasma membrane,
endosomes and the Golgi suggests a protein trafficking
function [180,181]. Recently it was found that SorLA/
LR11 overexpression redistributed APP to the Golgi,
decreasing Ab generation, while SorLA/LR11 knockout
mice have increased levels of Ab,a sf o u n di nA D
patients [182]. Additionally, some inherited variants of
the SorLA/LR11 gene were found to associate with late-
onset AD [183].
Low-density lipoprotein receptor-related protein (LRP)
is a SorLA/LR11-related protein that binds to APP
through Fe65, a cytoplasmic adaptor protein [184]. LRP
has been shown to bind, directly or indirectly, with Ab
to mediate its clearance [185,186]. Antagonizing the
extracellular interaction between cell-surface APP and
LRP increased the level of cell surface APP while
decreasing Ab generation [187]. Using an AD mouse
model, expression of a functional LRP minireceptor in
neurons resulted in increased memory deficits and
higher Ab levels in the aged mice [188]. An LRP-related
protein 1B (LRP1B) has a similar effect, binding APP at
the plasma membrane, preventing APP internalization,
and leading to decreased Ab generation and increased
sAPPa secretion [189].
Signal transduction
Epidemiological evidence suggests that post-menopausal
women receiving replacement therapy of the sex hor-
mone estrogen have a reduced risk and delayed onset of
AD while elderly women with reduced levels of circulat-
ing estrogen have an increased incidence of AD
[190-192]. The primary mechanism of estrogen’s protec-
tion against AD development is still unclear. Several
potential mechanisms have been proposed: (1) estrogen
may act on interlukin 6 to antagonize inflammation
[193]; (2) the phenolic structure of estrogen may contri-
bute to its antioxidant effect in cells [194]; (3) estrogen
may reduce the level of appolipoprotein E (ApoE), with
the isoform ApoE4 being a strong risk factor for AD
development [195]; and (4) gonadal steroids may reduce
the protein level of PS1 and thus g-secretase activity
[196].
We have found that estrogen may reduce Ab levels by
stimulating the a-secretase pathway and thereby inhibit
Ab generation. Estrogen can stimulate the formation of
APP-containing vesicles from the TGN in cell-free sys-
tems derived from both neuroblastomas and primary
neurons [197-199]. Interestingly, the stimulation of
sAPPa secretion by estrogen can be blocked by a PKC
Zhang et al. Molecular Brain 2011, 4:3
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dependent pathway [200]. Indeed, phorbol ester’s effect
on sAPPa secretion and Ab generation though activation
of protein kinase C (PKC) has been known for a long
time [201-203]. PKC stimulates sAPPa secretion, redu-
cing Ab l e v e l s ,e v e nw h e nt h ep h o s p h o r y l a t i o ns i t e so n
APP are mutated or the entire cytoplasmic domain is
deleted [204]. While PKC can directly phosphorylate
APP Ser655 [205], it appears to affect APP metabolism
by phosphorylating a different target. One potential tar-
get is a TGN phosphoprotein, resulting in transport of
APP from the TGN to the cell surface. Our studies have
shown that PKC increases the formation of APP-contain-
ing secretory vesicles from the TGN in a cell-free system
[206]. In support of this, protein kinase A (PKA) has
similar effects on reducing Ab generation and stimulating
the budding of APP-containing vesicles from the TGN
[207]. The effects of PKC and PKA are additive, suggest-
ing that while they both appear to act through stimulat-
ing vesicle formation from the TGN, the regulatory
mechanisms involved are independent [207]. Addition-
ally, estrogen has been found to facilitate binding of
Rab11 to the TGN membrane and a dominant negative
Rab11 mutant abolishes the estrogen-regulated change in
APP trafficking, leading to increased Ab formation [197].
The sex hormone testosterone decreases with age in
older men and postmenopausal women. Animal model
studies of testosterone treatments show neuroprotective
and neuroexcitatory benefits along with improved cogni-
tive performance [208]. Some studies have suggested
that testosterone exerts its beneficial effect through an
aromatase-mediated conversion into estrogen [209,210].
However, a recent study blocking the conversion of tes-
tosterone to estrogen found an estrogen-independent
improvement in cognitive function and lowering of pla-
que formation along with a decrease in BACE1 mRNA,
protein level, and activity [211]. In addition, testosterone
may also reduce the protein level of PS1 [196].
Conclusion
The overproduction and accumulation of Ab in the brain
are key pathogenic events in AD progression. In addition
to Ab, APP can be proteolyzed by different secretases and
caspases. In this review we have discussed APP processing
regulation and the physio/pathological functions of various
APP metabolites. Further elucidation of APP metabolism
will be important for identifying new potential therapies to
reduce Ab accumulation and combat AD.
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